Key players operating in the anatomic pathology market include F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), Agilent Technologies (U.S.), Sakura Finetechnical Co., Ltd. (Japan), Quest Diagnostics Incorporated (U.S.), Laboratory Corporation of America Holdings (U.S.), and NeoGenomics Laboratories, Inc. (U.S.)
The anatomic pathology market is expected to reach USD 21.9 Billion by 2021 from USD 16.2 Billion in 2016, at a CAGR of 6.1%.
Based on region, the global market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, the Asian region is expected to witness the highest growth during the forecast period. The presence of emerging economies like China, India, and Japan; the large population and rising prevalence of chronic diseases in these countries; improving standards of living; growing demand for quality medical care; increasing healthcare spending and government initiatives; rising awareness about the use of anatomic pathology tests among physicians; and growth in the demand for diagnostics are some major factors driving the high growth of this regional segment.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=137323145
The global anatomic pathology market is segmented on the basis of product & service and application. Anatomic pathology involves the diagnosis of various types of cancer, infectious diseases, and medical conditions through the examination of cells and tissue samples, which are collected from patients through biopsy. The market is witnessing high growth due to factors such as increasing prevalence of chronic diseases, growing aging population, and increasing healthcare expenditure.